MiCAN Technologies

MiCAN Technologies has technologies and licenses to produce high function human myeloid lineage cells (Mylc) from human iPS cells. The development and the feasibility studies to launch the cMylc has been conducted with a collaboration to the Research Institute for Microbial Diseases at Osaka University.

Business information

Company name

MiCAN Technologies

Established

2016

Location

Kyoto, JP

Spinout from

Independent

Other location(s)

Kobe, JP

Technology validation

TRL

7

Value of patent(s)

No data

Business stage

Spinout / Seed fund stage

Target exit

IPO in other country

Next investment requirement

Message to the business partners

MiCAN is looking for global R&D partners to evaluate our iPS derived dendric myeloid cells in the applications of dengue virus and COVID-19 (SARS-CoV-2) research. Also looking for global supply chain partners (distributors) to handle our ready-to-use kit accessible to the global scientists.